NCT01160861View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

July 11, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Allergic Rhinitis

Interventions

DRUG

MEMP1972A

Repeating ascending dose

DRUG

placebo

Repeating ascending dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY